IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD-Reference-Cited by-同舟云学术

IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD

Published:2012-11-19 Issue:5 Volume:48 Page:722-728
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Pratt L M,Liu Y,Ugarte-Torres A,Hoegh-Petersen M,Podgorny P J,Lyon A W,Williamson T S,Khan F M,Chaudhry M A,Daly A,Stewart D A,Russell J A,Grigg A,Ritchie D,Storek J

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2012210.pdf

Reference45 articles.

1. Pavletic SZ, Vogelsang GB . Chronic graft-vs-host disease: clinical manifestations and therapy. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas’ Hematopoietic Cell Transplantation. Blackwell Publishing, 2009 pp 1304–1324.

2. Socie G, Ritz J, Martin PJ . Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16 (1 Suppl): S146–S151.

3. Shlomchik WD . Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340–352.

4. Martin PJ, Pavletic SZ . Biology and management of chronic graft-versus-host disease. Cancer Treat Res 2009; 144: 277–298.

5. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances and research progress in biomarkers for chronic graft versus host disease;Critical Reviews in Oncology/Hematology;2023-06

2. Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review;Frontiers in Immunology;2022-10-25

3. The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia;Stem Cell Reviews and Reports;2022-08-22

4. A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin;CYTOTHERAPY;2021

5. A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin;Cytotherapy;2021-11